Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Hirschberger

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Chemical Theory and Computation|December 8, 2015
Extracting Markov Models of Peptide Conformational Dynamics from Simulation DataVerena Schultheis, Thomas Hirschberger, Heiko Carstens, et al.
Biophysical Journal|March 4, 2006
Structural instability of the prion protein upon M205S/R mutations revealed by molecular dynamics simulationsThomas Hirschberger, Martina Stork, Bernhard Schropp, et al.
Biochemical and Biophysical Research Communications|February 8, 2014
Piperazine derivatives inhibit PrP/PrP(res) propagation in vitro and in vivoFabienne Leidel, Martin Eiden, Markus Geissen, et al.
Antimicrobial Agents and Chemotherapy|July 13, 2011
Diphenylpyrazole-derived compounds increase survival time of mice after prion infectionFabienne Leidel, Martin Eiden, Markus Geissen, et al.
The Journal of Biological Chemistry|December 16, 2006
Identification of anti-prion compounds as efficient inhibitors of polyglutamine protein aggregation in a zebrafish modelNiclas W Schiffer, Sarah A Broadley, Thomas Hirschberger, et al.
Journal of Virology|May 28, 2005
Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targetsUwe Bertsch, Konstanze F Winklhofer, Thomas Hirschberger, et al.
Chemmedchem|July 15, 2011
From high-throughput cell culture screening to mouse model: identification of new inhibitor classes against prion diseaseMarkus Geissen, Fabienne Leidel, Martin Eiden, et al.
Acta Neuropathologica|April 23, 2013
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's diseaseJens Wagner, Sergey Ryazanov, Andrei Leonov, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Chemical Theory and Computation|December 8, 2015
Extracting Markov Models of Peptide Conformational Dynamics from Simulation DataVerena Schultheis, Thomas Hirschberger, Heiko Carstens, et al.
Biophysical Journal|March 4, 2006
Structural instability of the prion protein upon M205S/R mutations revealed by molecular dynamics simulationsThomas Hirschberger, Martina Stork, Bernhard Schropp, et al.
Biochemical and Biophysical Research Communications|February 8, 2014
Piperazine derivatives inhibit PrP/PrP(res) propagation in vitro and in vivoFabienne Leidel, Martin Eiden, Markus Geissen, et al.
Antimicrobial Agents and Chemotherapy|July 13, 2011
Diphenylpyrazole-derived compounds increase survival time of mice after prion infectionFabienne Leidel, Martin Eiden, Markus Geissen, et al.
The Journal of Biological Chemistry|December 16, 2006
Identification of anti-prion compounds as efficient inhibitors of polyglutamine protein aggregation in a zebrafish modelNiclas W Schiffer, Sarah A Broadley, Thomas Hirschberger, et al.
Journal of Virology|May 28, 2005
Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targetsUwe Bertsch, Konstanze F Winklhofer, Thomas Hirschberger, et al.
Chemmedchem|July 15, 2011
From high-throughput cell culture screening to mouse model: identification of new inhibitor classes against prion diseaseMarkus Geissen, Fabienne Leidel, Martin Eiden, et al.
Acta Neuropathologica|April 23, 2013
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's diseaseJens Wagner, Sergey Ryazanov, Andrei Leonov, et al.
Pageof 1